Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Current and emerging strategies to treat urothelial carcinoma
Simple Summary Urothelial cell carcinoma (UCC) is the ninth most common cancer
worldwide and in the US the fourth most common cancer, with~ 82,000 new cases (~ 62,000 …
worldwide and in the US the fourth most common cancer, with~ 82,000 new cases (~ 62,000 …
RP-HPLC can be used to determine an Enfortumab vedotin monoclonal antibody drug conjugate for treating urothelial cancer in an efficient rapid and quantitative …
CSR Gurugubelli, S Pallapati… - Analytical Chemistry …, 2025 - Taylor & Francis
Enfortumab vedotin (EV) is an antibody-drug conjugate that's applied to the treatment of
urothelial carcinoma, or bladder cancer. EV was a microtubule-disrupting chemotherapeutic …
urothelial carcinoma, or bladder cancer. EV was a microtubule-disrupting chemotherapeutic …
[PDF][PDF] Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral.
GC Gaona Neira, SD Salazar Prieto… - Ciencia en …, 2023 - revistas.uptc.edu.co
El melanoma es un tumor maligno que surge por alteraciones de los melanocitos, que
desencadenan la pérdida de control de los mecanismos de crecimiento y proliferación …
desencadenan la pérdida de control de los mecanismos de crecimiento y proliferación …
[PDF][PDF] Emerging Novel Therapies to Treat Urothelial Carcinoma
B Rani, JJ Ignatz-Hoover, PS Rana, JJ Driscoll - 2023 - preprints.org
Urothelial cell carcinoma (UCC, bladder cancer) remains a difficult to treat malignancy with
rising incidence worldwide. In the US, UCC is the sixth most incident neoplasm and~ 90% of …
rising incidence worldwide. In the US, UCC is the sixth most incident neoplasm and~ 90% of …